Pharma Stock Roundup: J&J's Mixed Q4, Roche & Novartis' New Drugs Approval in EU

by Kinjel Shah Published on January 24,2020

J&J (JNJ) announces mixed Q4 results. Roche's (RHHBY) lymphoma drug, Polivy and Novartis' (NVS) Mayzent for secondary progressive multiple sclerosis (SPMS) get approval in Europe.

• MRK Quick QuoteMRKNegative Net Change
• PFE Quick QuotePFENegative Net Change
• AZN Quick QuoteAZNPositive Net Change
• RHHBY Quick QuoteRHHBYPositive Net Change
• GSK Quick QuoteGSKPositive Net Change
• JNJ Quick QuoteJNJPositive Net Change
• NVS Quick QuoteNVSNegative Net Change

• pharmaceuticals

Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258

by Zacks Equity Research Published on January 23,2020

Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.

• NVS Quick QuoteNVSNegative Net Change
• AVDL Quick QuoteAVDLPositive Net Change
• JAZZ Quick QuoteJAZZPositive Net Change
• TEVA Quick QuoteTEVAPositive Net Change

• pharmaceuticals

Roche's Risdiplam Meets Primary Endpoint in Infants Study

by Zacks Equity Research Published on January 23,2020

Roche's (RHHBY) risdiplam meets primary endpoint in FIREFISH study in infants with type 1 spinal muscular atrophy.

• RHHBY Quick QuoteRHHBYPositive Net Change
• NVS Quick QuoteNVSNegative Net Change
• BIIB Quick QuoteBIIBNegative Net Change
• PTCT Quick QuotePTCTPositive Net Change

• medical
• pharmaceuticals

Novartis (NVS) Gets Approval for MS Drug Mayzent in Europe

by Zacks Equity Research Published on January 21,2020

Novartis' (NVS) MS drug, Mayzent, obtains approval in Europe for the treatment of adult patients with secondary progressive multiple sclerosis.

• NVS Quick QuoteNVSNegative Net Change
• BIIB Quick QuoteBIIBNegative Net Change
• MNTA Quick QuoteMNTAPositive Net Change
• TEVA Quick QuoteTEVAPositive Net Change

• medical
• pharmaceuticals

Puma Biotech's (PBYI) Breast Cancer Drug Nerlynx Aids Growth

by Zacks Equity Research Published on January 21,2020

Puma Biotech (PBYI) focuses on improving sales of its only marketed drug Nerlynx, which is approved for treating breast cancer. The drug's label expansion programs also look promising.

• RHHBY Quick QuoteRHHBYPositive Net Change
• NVS Quick QuoteNVSNegative Net Change
• PBYI Quick QuotePBYIPositive Net Change
• EPZM Quick QuoteEPZMPositive Net Change

• biotechs

Jazz's (JAZZ) New Sleep Drug Sunosi Gets Approval in Europe

by Zacks Equity Research Published on January 21,2020

Jazz (JAZZ) receives approval for Sunosi as a treatment for excessive daytime sleepiness in narcolepsy or obstructive sleep apnea patients in Europe.

• NVS Quick QuoteNVSNegative Net Change
• AVDL Quick QuoteAVDLPositive Net Change
• JAZZ Quick QuoteJAZZPositive Net Change
• TEVA Quick QuoteTEVAPositive Net Change

• pharmaceuticals

Is Novartis AG (NVS) A Suitable Pick for Value Investors?

by Zacks Equity Research Published on January 20,2020

Is Novartis AG (NVS) a great pick from the value investor's perspective right now? Read on to know more.

• NVS Quick QuoteNVSNegative Net Change

• undervalued-stocks
• value-stocks

Will J&J (JNJ) Roll Out Pharma Q4 Earnings With a Beat?

by Zacks Equity Research Published on January 17,2020

J&J's (JNJ) cancer drugs are expected to have contributed significantly to fourth-quarter 2019 earnings. Generic/biosimilar headwinds are expected to have hurt Pharma unit's sales.

• JNJ Quick QuoteJNJPositive Net Change
• MRK Quick QuoteMRKNegative Net Change
• NVS Quick QuoteNVSNegative Net Change
• REGN Quick QuoteREGNNegative Net Change

• pharmaceuticals

Pharma Stock Roundup: LLY Dermira Buyout Offer, Pipeline & Regulatory Updates

by Kinjel Shah Published on January 17,2020

Lilly (LLY) offers to buy Dermira for $1.1 billion. AstraZeneca (AZN) and AbbVie (ABBV) provide pipeline updates.

• MRK Quick QuoteMRKNegative Net Change
• JNJ Quick QuoteJNJPositive Net Change
• BMY Quick QuoteBMYPositive Net Change
• ABBV Quick QuoteABBVNegative Net Change
• AZN Quick QuoteAZNPositive Net Change
• NVS Quick QuoteNVSNegative Net Change
• LLY Quick QuoteLLYPositive Net Change

• pharmaceuticals

Alnylam Provides Preliminary Q4 Sales for Onpattro & Givlaari

by Zacks Equity Research Published on January 13,2020

Alnylam (ALNY) announces preliminary results for the fourth quarter and 2019 and provides other updates.

• NVS Quick QuoteNVSNegative Net Change
• ALNY Quick QuoteALNYPositive Net Change
• ALXN Quick QuoteALXNPositive Net Change
• CUE Quick QuoteCUEPositive Net Change

• biotechs

Regeneron's Phase II Candidate Promising in Primary Analysis

by Zacks Equity Research Published on January 10,2020

Regeneron (REGN) announces encouraging results from the phase II study on rare bone disease candidate.

• NVS Quick QuoteNVSNegative Net Change
• SNY Quick QuoteSNYNegative Net Change
• BAYRY Quick QuoteBAYRYPositive Net Change
• REGN Quick QuoteREGNNegative Net Change

• biotechs

The Zacks Analyst Blog Highlights: Novartis, McDonald's, Bristol-Myers Squibb, CME and UBS

by Zacks Equity Research Published on January 10,2020

The Zacks Analyst Blog Highlights: Novartis, McDonald's, Bristol-Myers Squibb, CME and UBS

• NVS Quick QuoteNVSNegative Net Change
• BMY Quick QuoteBMYPositive Net Change
• UBS Quick QuoteUBSPositive Net Change
• MCD Quick QuoteMCDPositive Net Change
• CME Quick QuoteCMEPositive Net Change

• finance
• medical

Top Analyst Reports for Novartis, McDonald's & Bristol-Myers Squibb

by Sheraz Mian Published on January 09,2020

Today's Research Daily features new research reports on 16 major stocks, including Novartis (NVS), McDonald's (MCD) and Bristol-Myers Squibb (BMY).

• UBS Quick QuoteUBSPositive Net Change
• NVS Quick QuoteNVSNegative Net Change
• MCD Quick QuoteMCDPositive Net Change
• CME Quick QuoteCMEPositive Net Change
• CB Quick QuoteCBPositive Net Change
• BMY Quick QuoteBMYPositive Net Change

• finance
• insurance
• pharmaceuticals
• restaurants

Incyte's (INCY) Itacitinib Fails in Late-Stage GVHD Study

by Zacks Equity Research Published on January 03,2020

Incyte (INCY) fails to meet goals in the phase III study on itacitinib for the treatment of first-line acute GVHD.

• MRK Quick QuoteMRKNegative Net Change
• NVS Quick QuoteNVSNegative Net Change
• INCY Quick QuoteINCYNegative Net Change
• ALXN Quick QuoteALXNPositive Net Change

• biotechs

Glaxo (GSK) Shares Continue to Witness Upside: Here's Why

by Zacks Equity Research Published on January 03,2020

Glaxo's (GSK) successful product launches, increasing focus on the oncology area, and positive pipeline and regulatory updates are driving the stock.

• GSK Quick QuoteGSKPositive Net Change
• PFE Quick QuotePFENegative Net Change
• JNJ Quick QuoteJNJPositive Net Change
• NVS Quick QuoteNVSNegative Net Change

Global Blood (GBT) Shares Double in a Year, Focus on Oxbryta

by Zacks Equity Research Published on January 02,2020

Shares of Global Blood Therapeutics (GBT) have gained in the past year as its lead candidate voxelotor gets FDA approval for the treatment of SCD in patients aged 12 years or above.

• NVS Quick QuoteNVSNegative Net Change
• RHHBY Quick QuoteRHHBYPositive Net Change
• ALXN Quick QuoteALXNPositive Net Change
• GBT Quick QuoteGBTPositive Net Change

• biotechs

3 Biotech Stocks Likely to Maintain Solid Momentum in 2020

by Ekta Bagri Published on December 31,2019

With the biotech sector gaining steam in recent times, we shortlist three biotech stocks that are set to maintain momentum in 2020.

• NVS Quick QuoteNVSNegative Net Change
• BMY Quick QuoteBMYPositive Net Change
• ALXN Quick QuoteALXNPositive Net Change
• CLLS Quick QuoteCLLSPositive Net Change
• MDCO Quick QuoteMDCOPositive Net Change
• AMRN Quick QuoteAMRNNegative Net Change

• biotechs
• pharmaceuticals

Epizyme (EPZM) Shares Soar on Lead Candidate's Progress

by Zacks Equity Research Published on December 26,2019

Epizyme's (EPZM) shares soar year to date on positive developments for its lead pipeline candidate tazemetostat being evaluated for the treatment of solid tumors and hematological malignancies

• PFE Quick QuotePFENegative Net Change
• RHHBY Quick QuoteRHHBYPositive Net Change
• NVS Quick QuoteNVSNegative Net Change
• EPZM Quick QuoteEPZMPositive Net Change

• biotechs

Incyte (INCY) Surges 44% YTD on Jakafi's Strong Performance

by Zacks Equity Research Published on December 26,2019

Incyte (INCY) outperforms the industry year to date on strong Jakafi sales.

• LLY Quick QuoteLLYPositive Net Change
• NVS Quick QuoteNVSNegative Net Change
• ALXN Quick QuoteALXNPositive Net Change
• INCY Quick QuoteINCYNegative Net Change

• biotechs
• pharmaceuticals

Biotech Leading in Q4: Best ETFs & Stocks

by Sweta Killa Published on December 24,2019

We highlight five biotech ETFs and stocks that are leading the market in Q4.

• SNY Quick QuoteSNYNegative Net Change
• MRK Quick QuoteMRKNegative Net Change
• RHHBY Quick QuoteRHHBYPositive Net Change
• NVS Quick QuoteNVSNegative Net Change
• CNCR Quick QuoteCNCRPositive Net Change
• SBIO Quick QuoteSBIOPositive Net Change
• XBI Quick QuoteXBIPositive Net Change
• BBC Quick QuoteBBCPositive Net Change
• THOR Quick QuoteTHORPositive Net Change
• SRPT Quick QuoteSRPTNegative Net Change
• GBT Quick QuoteGBTPositive Net Change
• VRTX Quick QuoteVRTXNegative Net Change
• AXSM Quick QuoteAXSMNegative Net Change
• CLSD Quick QuoteCLSDNegative Net Change

• biotechs
• etfs

Allergan (AGN) Gets FDA Approval for Migraine Drug Ubrelvy

by Zacks Equity Research Published on December 24,2019

Allergan (AGN) gets FDA nod for Ubrelvy for the acute treatment of migraine with or without aura in adults.

• LLY Quick QuoteLLYPositive Net Change
• AGN Quick QuoteAGNPositive Net Change
• NVS Quick QuoteNVSNegative Net Change
• TEVA Quick QuoteTEVAPositive Net Change

• pharmaceuticals

Pharma Stock Roundup: Lilly's Upbeat 2020 Outlook, FDA Nod for PFE & MRK's Drugs

by Kinjel Shah Published on December 20,2019

Lilly (LLY) issues upbeat financial guidance for 2020. FDA approves label expansion of Pfizer's (PFE) Xtandi and Merck's (MRK) Ebola vaccine, Ervebo.

• GSK Quick QuoteGSKPositive Net Change
• LLY Quick QuoteLLYPositive Net Change
• RHHBY Quick QuoteRHHBYPositive Net Change
• NVS Quick QuoteNVSNegative Net Change
• PFE Quick QuotePFENegative Net Change
• MRK Quick QuoteMRKNegative Net Change
• ABBV Quick QuoteABBVNegative Net Change

• pharmaceuticals

AbbVie's JAK Inhibitor Rinvoq Receives Approval for RA in EU

by Zacks Equity Research Published on December 19,2019

AbbVie's (ABBV) oral JAK inhibitor, upadacitinib, receives approval in Europe for treating rheumatoid arthritis under the trade name of Rinvoq.

• NVS Quick QuoteNVSNegative Net Change
• ABBV Quick QuoteABBVNegative Net Change
• AMGN Quick QuoteAMGNNegative Net Change
• BIIB Quick QuoteBIIBNegative Net Change

• pharmaceuticals

Novartis' Asthma Candidate Fails in LUSTER Phase III Studies

by Zacks Equity Research Published on December 17,2019

Novartis' (NVS) asthma candidate, fevipiprant, fails to meet endpoint in the phase III LUSTER studies.

• NVS Quick QuoteNVSNegative Net Change
• GSK Quick QuoteGSKPositive Net Change
• RHHBY Quick QuoteRHHBYPositive Net Change
• MRK Quick QuoteMRKNegative Net Change

• pharmaceuticals

Novartis Gets Positive CHMP Opinion for Wet AMD Drug Beovu

by Zacks Equity Research Published on December 16,2019

Novartis (NVS) obtains positive CHMP opinion for its wet AMD drug Beovu. A potential approval will boost its ophthalmology franchise.

• NVS Quick QuoteNVSNegative Net Change
• RHHBY Quick QuoteRHHBYPositive Net Change
• BAYRY Quick QuoteBAYRYPositive Net Change
• REGN Quick QuoteREGNNegative Net Change

• biotechs